Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Devacell Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. SALVOZA, M FRANCO G is identified as the busiest examiner, and the examination record is concentrated within a single examiner and art-unit setting. The profile presents a focused matter in the biotechnology and pharmaceutical field.
Counsel should review the action against the claimed biological subject matter, specification support, and available technical evidence. A focused record allows the response to maintain consistent claim language while addressing the examiner’s stated grounds directly. The data does not indicate multiple examination channels, so the practical priority is a disciplined response to this matter and careful preservation of useful positions for later prosecution.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.0% | +30.7% |
| PENNINGTON, KATIE LEIGH | 1 | 32.4% | +60.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | PENNINGTON, KATIE LEIGH | 13d |
| 18030956 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | SALVOZA, M FRANCO G | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | PENNINGTON, KATIE LEIGH | 13d |
| 18030956 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | SALVOZA, M FRANCO G | 70d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030956 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | SALVOZA, M FRANCO G | 1672 | §103§112Other | Non-Final OA | 70d | Pending | Apr 07, 2023 |
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | PENNINGTON, KATIE LEIGH | 1634 | §102§103§112Other | Final Rejection | 13d | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDevacell Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
M Franco G Salvoza has the most, with 1 of Devacell Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.